Changing course: SignalPath aims to reimagine research, accelerate tech-enabled clinical trials

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags Technical support Research Real world evidence Real world data Oncology Clinical trials Design

SignalPath is creating a research consortium through which it aims to leverage real world data to redesign clinical trials.

SignalPath, a health care technology and services company specializing in clinical research, has created the SignalPath Research Consortium, to bring together technology companies, life science sponsors, and research sites.

Brad Hirsch, CEO of SignalPath told us that the partnerships gained through the network will allow for the reimagining of clinical trials, powered by the technology that the sites use daily.

“While our technology at sites provides the foundation to support key functions like finance, operations, and startup, the need is broader. So we are working to bring our sites together through elements like education, community forums, and new trial opportunities,”​ said Hirsch

Companies like Florence Healthcare and Genentech will be joining forces with SignalPath to strengthen the consortium, which will include a network of clinical trial sites connected through a technical foundation.

The consortium will connect sites, sponsors, and research companies that will employ the software and data necessary for the development of oncology treatments more efficiently and affordable.

Hirsch told us, “Our goal is to grow the consortium in terms of sites and partners in order to reimagine the clinical trials that can be deployed across the ecosystem.”

By 2020, the company expects that it will be offering clinical trials that leverage real world experience in conjunction with its network sites, partners, and sponsors, said Hirsch.

SignalPath also will be working with the Biden Cancer initiative as a preview of how the consortium will deliver on the goals it has set. Hirsch said, “They [Biden Cancer Initiative] have been very helpful in bringing the group together and pushing to shrink timelines and drive productivity.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more